Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol’s Fibrotic Game Plan: Promedior Acquisition Hinges On Phase II Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol’s third deal in anti-fibrosis field in past year could give it intravenous, disease-modifying candidate for myelofibrosis and idiopathic fibrosis.

Advertisement

Related Content

Biopharma Quarterly Dealmaking Statistics, Q3 2015
Deal Watch: Bristol Continues Push Into Fibrotic Disease Area
$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications
Promedior Advances Novel Fibrotic Disease Therapy In Idiopathic Pulmonary Fibrosis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078868

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel